Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
To evaluate quality of life in patients after 10 days pause of thyroid medication
(Liothyronine) compared to treatment with recombinant TSH (Thyrogen) before radioiodine
uptake and treatment in a double-blinded, randomised cross-over design.